Pancreatic Cancer Research

ResearcherIstituto Scientifico Romagnolo per lo Studio e la Cura dei TumoriNo recent work listed

Alessandro Passardi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7099-240X; OpenAlex author ID A5087670194. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: none · 2023: 1 paper

Papers 11

  1. Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value. Co-author DOI 10.1016/j.omtm.2023.05.009↗
  2. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  3. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic can… Co-author DOI 10.1186/s12885-021-08368-5↗
  4. Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/biom11060780↗
  5. Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies. Co-author DOI 10.3390/biom11081200↗
  6. Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers … Co-author DOI 10.3390/cancers12010178↗
  7. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Co-author DOI 10.1016/j.clcc.2019.08.004↗
  8. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Co-author DOI 10.3390/cancers11050663↗
  9. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Co-author DOI 10.1016/j.ejca.2013.06.041↗
  10. Treatment trends in metastatic pancreatic cancer patients: Is it time to change? Co-author DOI 10.1016/j.dld.2010.09.010↗
  11. GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. Co-author PMID 21661438↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ilario Giovanni Rapposelli · 4 shared papers, 2021–2023 · strength 0.51
  2. Antonino Romeo · 4 shared papers, 2011–2021 · strength 0.31
  3. Giorgio Ercolani · 3 shared papers, 2019–2021 · strength 0.29
  4. Caterina Vivaldi · 2 shared papers, 2019–2021 · strength 0.20
  5. Andrea Gardini · 2 shared papers, 2019–2020 · strength 0.18
  6. Ivan Vannini · 1 shared paper, 2023 · strength 0.15
  7. Andrea Mambrini · 3 shared papers, 2011–2021 · strength 0.15
  8. Michèle Milella · 3 shared papers, 2011–2021 · strength 0.15
  9. Alessandro Cucchetti · 1 shared paper, 2021 · strength 0.13
  10. Valentina Arcangeli · 1 shared paper, 2021 · strength 0.11
  11. Rita Danesi · 1 shared paper, 2021 · strength 0.11
  12. Valentina Zampiga · 1 shared paper, 2021 · strength 0.11
  13. Giuseppe Malleo · 1 shared paper, 2021 · strength 0.10
  14. Filippo Scopelliti · 1 shared paper, 2021 · strength 0.10
  15. Paolo Regi · 1 shared paper, 2021 · strength 0.10
  16. Alessandro Giardino · 1 shared paper, 2021 · strength 0.10
  17. Maurizio Cantore · 1 shared paper, 2021 · strength 0.10
  18. Roberto Girelli · 1 shared paper, 2021 · strength 0.10
  19. Giammaria Fiorentini · 1 shared paper, 2021 · strength 0.10
  20. Isabella M. Frigerio · 1 shared paper, 2021 · strength 0.10
  21. Giovanni Butturini · 1 shared paper, 2021 · strength 0.10
  22. Mirko D’Onofrio · 1 shared paper, 2021 · strength 0.10
  23. Roberto Bianco · 1 shared paper, 2021 · strength 0.10
  24. Gabriella Lionetto Lionetto · 1 shared paper, 2021 · strength 0.10
  25. Claudio Bassi · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.